-+ 0.00%
-+ 0.00%
-+ 0.00%

Wedbush Reiterates Outperform on ORIC Pharmaceuticals, Maintains $20 Price Target

Benzinga·12/08/2025 14:08:05
Listen to the news
Wedbush analyst David Nierengarten reiterates ORIC Pharmaceuticals (NASDAQ:ORIC) with a Outperform and maintains $20 price target.